Lower-cost GLP-1 obesity medicines could mark the next major shift in the global diabetes and obesity market
Keep away from children!
Sign up for the Barrick Health Insider newsletter for ongoing coverage of the Bridge, BALANCE updates as they come, and the clinical detail that does not make it into the press releases
it just requires some added context
Listed Products of GLP-1 Receptor Agonists (GLP-1RA) At present, 9 GLP-1 receptor agonist hypoglycemic drugs have been approved for marketing in the world, namely: exenatide, liraglutide, Exenatide extended-release (exenatide ER), albiglutide, dulaglutide , lixisenatide, benaglutide, semaglutide, polyethylene glycol loxenatide injection and oral semaglutide
LtscherJMart i LndezA-AKirchhammerNCribioliEGiordano AttianeseGMPTrefnyMPet al